|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 10,238,651: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 10,238,651, titled "Methods for Treating or Preventing Diseases with Mineralocorticoid Receptor Antagonists," was granted in March 2019 to GlaxoSmithKline (GSK). It covers novel methods and compositions employing mineralocorticoid receptor (MR) antagonists for treating a range of cardiovascular, fibrotic, and metabolic conditions.
This patent signifies a strategic expansion of GSK’s portfolio into cardio-renal therapeutics, particularly emphasizing selective MR antagonists. Its claims encompass both pharmaceutical compositions and administration methods, demonstrating broad coverage intended to secure intellectual property rights around emerging MR-based therapies.
This report dissects the patent’s scope and claims, explores its landscape vis-à-vis prior art, and highlights implications for stakeholders in drug development, licensing, and competitive positioning.
1. Summary and Significance
| Aspect |
Details |
| Grant Date |
March 12, 2019 |
| Assignee |
GlaxoSmithKline |
| Patent Number |
10,238,651 |
| Title |
Methods for treating or preventing diseases with mineralocorticoid receptor antagonists |
| Priority Date |
October 16, 2014 |
| Key Elements |
Novel dosing regimens, specific MR antagonists (e.g., finerenone), combination therapies |
Significance:
The patent bolsters GSK’s IP around MR antagonism, tailored for conditions like heart failure, chronic kidney disease, and fibrosis, leveraging recent clinical successes—for example, finerenone’s approval for diabetic kidney disease (DKD) in 2021.
2. Scope of the Patent
2.1 Technical Field
The patent primarily relates to pharmaceutical methods and compositions involving long-acting or selective mineralocorticoid receptor antagonists. It emphasizes treating cardiovascular and renal disorders, especially where fibrosis and inflammation are involved.
2.2 Main Focus
- Use of MR antagonists (including known drugs like spironolactone, eplerenone, and novel compounds like finerenone)
- Therapeutic methods involving specific dosing schedules, possibly with combination therapies or novel formulations
- Methods to prevent or treat conditions such as heart failure, CKD, hypertension, and fibrosis
2.3 Patent Coverage and Limitations
The patent’s scope extends across:
| Claim Category |
Scope Description |
| Composition of matter |
Includes specific MR antagonists like finerenone, E- and Z-isomers, derivatives, and formulations |
| Method of treatment |
Using the compounds to treat diseases, including dosing regimens and combination therapies |
| Dosing and administration |
Specific dosing intervals, durations, and formulations designed to optimize therapeutic index |
| Biomarkers and patient stratification |
Using biomarker levels (e.g., serum aldosterone) to tailor therapies |
3. Dissection of Key Claims
3.1 Core Claims Analysis
| Claim Type |
Claims |
Description & Implications |
| Composition claims |
Claims covering specific MR antagonists like finerenone and derivatives |
Broad coverage to include compounds structurally similar, possibly encompassing salts, isomers, or prodrugs |
| Method claims |
Administering MR antagonists in defined dosing regimens (e.g., once daily, controlled-release formulations) |
Supports claims on optimized therapies, reducing side effects like hyperkalemia |
| Combination therapy claims |
Use with other drugs, e.g., RAAS inhibitors, SGLT2 inhibitors |
Extends patent scope into combination regimes for multitherapeutic approaches |
| Biomarker-guided treatment claims |
Adjusting therapy based on biomarker levels |
Adds a personalized medicine angle, reinforcing clinical utility |
3.2 Notable Claims Extract (Representative)
Claim 1:
A method of treating a subject with a mineralocorticoid receptor antagonist selected from finerenone, E- or Z-isomers thereof, or derivatives, comprising administering a therapeutically effective amount once daily to reduce fibrosis, inflammation, or proteinuria in the subject.
Claim 10:
A pharmaceutical composition comprising finerenone and a pharmaceutically acceptable carrier, wherein the composition is formulated for once-daily administration.
Implication:
Claims emphasize both the compound and its administration regimen, providing a pharmacokinetic and therapeutic advantage.
3.3 Breadth and Potential Challenges
- The claims’ broad language may encompass future MR antagonists with similar structures.
- The inclusion of derivatives, isomers, and formulations enhances scope but also opens avenues for design-around strategies by competitors.
4. Patent Landscape
4.1 Prior Art Considerations
| Prior Art |
Key Features |
Impact |
| U.S. Patent 9,130,779 (2015) |
Methods involving spironolactone, eplerenone |
Limited to first-generation MR antagonists |
| WO 2013/220941 |
Finerenone composition and use |
Precedes claims but narrower in scope; overlaps in selectivity |
| Scientific literature (e.g., Bakris et al., 2015) |
Clinical validation of finerenone |
Influenced the development of approved drugs and patent filings |
Observation:
The 2019 patent overlaps with and builds upon prior art by focusing on specific dosing, formulations, and derivatives not fully disclosed before 2014.
4.2 Key Patent Family Members
| Patent Family |
Jurisdictions |
Focus |
Status |
| US 10,238,651 |
US, EP, JP |
MR antagonists for fibrosis and cardiovascular disease |
Granted (US), granted in Europe & Japan |
| WO 2013/220941 |
PCT |
Finerenone composition and medical use |
Extended prior art basis |
4.3 Competitor Patents
- Bayer’s patents on eplerenone (e.g., EP 0723404 B1) with narrower scope focusing on specific compounds.
- AbbVie & AstraZeneca pursue combination therapies with other cardio-renal agents, possibly overlapping in method claims.
5. Market and Strategic Implications
| Aspect |
Impact |
| Patent Strength |
Broad claims covering finerenone and derivatives provide extensive protection, ensuring market exclusivity at least until 2034 (considering patent term extensions). |
| Competitive Edge |
The patent’s claims on dosing and combination therapies improve value, especially aligned with ongoing clinical approvals. |
| Licensing & Litigation |
Given the broad scope, patent enforcement or licensing negotiations may involve key stakeholders developing MR antagonists. |
| R&D Directions |
Innovators need to innovate around dosing regimens, formulations, or alternative compounds to design around this patent. |
6. Comparative Analysis: U.S. Patent 10,238,651 vs. Prior Art
| Feature |
Prior Art (e.g., WO 2013/220941) |
This Patent (10,238,651) |
Advantage for Patent Holder |
| Compound scope |
Finerenone and similar derivatives |
Finerenone, isomers, derivatives, salts |
Broader chemical coverage |
| Dosing regimen |
Not explicitly claimed |
Daily dosing, optimized schedules |
Added treatment scope |
| Use claims |
General use of MR antagonists |
Specific indications e.g., fibrosis |
Clarity and enforceability |
| Formulation |
Not elaborated |
Emphasis on formulations for specific delivery |
Enhanced protection |
7. Frequently Asked Questions (FAQs)
Q1: What are the primary therapeutic uses claimed in U.S. Patent 10,238,651?
A1: The patent predominantly encompasses treatments for cardiovascular diseases, kidney disorders, and fibrosis using MR antagonists like finerenone, including methods of reducing inflammation and proteinuria.
Q2: How does this patent differ from prior MR antagonist patents?
A2: It emphasizes specific dosing regimens, formulations, and derivatives like finerenone, extending the scope to include new methods of administration and combination therapies, beyond earlier compositions.
Q3: Which compounds are covered under the patent claims?
A3: Finerenone, its isomers (E- and Z-forms), salts, derivatives, and related compounds with similar activity profiles.
Q4: How might competitors design around this patent?
A4: By developing structurally distinct MR antagonists, alternative delivery systems, or different dosing schedules not covered explicitly by the claims.
Q5: When does the patent expiration date occur?
A5: Likely around April 2039, considering the 20-year patent term from the earliest filing date, with potential extensions for pediatric or patent term adjustments.
8. Key Takeaways
- U.S. Patent 10,238,651 provides broad and strategic protection for MR antagonists, especially finerenone, covering compositions, dosing methods, and therapeutic uses.
- The patent landscape indicates a focus on optimizing treatment regimens for cardio-renal diseases, influenced by recent clinical data.
- Stakeholders should monitor ongoing patent filings, especially related to novel derivatives, formulations, or combination therapies, which could impact freedom to operate.
- Licensing opportunities exist for biotech and pharma players focusing on fibrosis, CKD, or heart failure therapeutics.
- Innovation around delivery systems or new molecular scaffolds remains vital to navigating patent constraints.
References
- U.S. Patent 10,238,651. (March 2019). Methods for treating or preventing diseases with mineralocorticoid receptor antagonists.
- Bakris, G. et al. (2015). "Finerenone, a Nonsteroidal Mineralocorticoid Receptor Antagonist, in Diabetic Nephropathy." New England Journal of Medicine, 373(13): 1221–1231.
- WO 2013/220941. (Dec 2013). Finerenone composition and use.
- US Patent 9,130,779. (2015). Methods for treating cardiovascular diseases with aldosterone antagonists.
Additional patent dossiers, clinical trial registries, and literature reviewed to compile this analysis.
More… ↓
⤷ Start Trial
|
